# Final Governance & Version-Control Consistency Audit Report

**Document Title:** Final Pre-Submission Governance Consistency Audit  
**Date of Audit:** 2026-09-30  
**Target Protocol:** Phase 6 Clinical Validation Protocol (Version 2.1)  
**Lead Auditor:** Antigravity Regulatory & Diagnostic Assurance System  
**Audit Purpose:** Comprehensive cross-document consistency verification across clinical protocol, reference standard SOP, statistical analysis plan, machine learning configurations, STARD-AI checklist, and ethics submission package.  
**Overall Result:** **PASS (ALL 8 AUDIT DOMAINS PASSED)**  
**Final Status:** **`FINAL_STATUS = READY_FOR_ETHICS_SUBMISSION`**  

---

## 1. Governance Domain Consistency Evaluations

### Domain 1: Reference Analyzer Consistency
* **Audit Standard:** Exact primary reference analyzer models, site mappings, sample types, and quality control specifications must be harmonized across all protocol documents, configuration JSONs, and SOPs.
* **Findings:**
  - `configs/clinical_protocol_version.json`: `Sysmex XN-350 / Sysmex XN-550 Automated Hematology Analyzers (Venous EDTA whole blood)`
  - `docs/phase_6_clinical_protocol.md`: `Sysmex XN-350 / Sysmex XN-550` on Venous EDTA Whole Blood
  - `docs/phase_6_reference_standard_sop.md`: `Sysmex XN-350 / XN-550` with SLS cyanide-free spectrophotometric method ($555\text{ nm}$)
  - Site Mapping: Site A (Princess Marie Louise / Korle Bu) $\to$ Sysmex XN-550; Site B (Ga West Municipal) $\to$ Sysmex XN-350; Site C (Central Region) $\to$ cold-chain transit to Ga West central laboratory (Sysmex XN-350).
  - Secondary Comparator: `HemoCue Hb 301 System` strictly designated as secondary point-of-care microcuvette comparator.
* **Status:** **PASS**

---

### Domain 2: Target Population Consistency
* **Audit Standard:** Primary prospective validation cohort must be strictly locked to children aged 6 to 59 months with age-stratified WHO cutoffs. Infants 0–5 months must be segregated into an exploratory non-primary arm. Adults and Fitzpatrick I–III must be explicitly stated as non-validated.
* **Findings:**
  - Primary Age Range: **Children aged 6 to 59 months** (verified across protocol, SAP, JSON config, STARD-AI checklist).
  - Explicit Non-Claims: Adult performance is NOT validated; 0–5m infant performance is NOT validated in primary study; non-African Fitzpatrick I–III phototypes are NOT validated.
* **Status:** **PASS**

---

### Domain 3: Diagnostic Label Consistency
* **Audit Standard:** Ground-truth anemia definitions must adhere strictly to WHO 2024 pediatric guidelines:
  - $6\text{--}23\text{ months}$: $\text{Anemia if Hb} < 10.5\text{ g/dL}$ ($105\text{ g/L}$)
  - $24\text{--}59\text{ months}$: $\text{Anemia if Hb} < 11.0\text{ g/dL}$ ($110\text{ g/L}$)
* **Findings:**
  - Verified identical mathematical definitions across `docs/phase_6_clinical_protocol.md`, `docs/STARD_AI_checklist.md`, `reports/phase_6_sample_size_justification.md`, and `configs/clinical_protocol_version.json`.
* **Status:** **PASS**

---

### Domain 4: Model Versioning & Artifact Consistency
* **Audit Standard:** Model name, architecture, version tags, calibration method, threshold version, and preprocessing specifications must be frozen and identical across code and documentation.
* **Verified Values:**
  - `model_name`: `"EfficientNet-B0"`
  - `model_version`: `"efficientnet_b0_v001"`
  - `calibration_version`: `"isotonic_regression_v001"`
  - `threshold_version`: `"locked_tau_0.48"`
  - `preprocessing_version`: `"nail_roi_224x224_rgb_v1.0.0"`
  - `development_dataset_version`: `"frozen_ghana_cohort_552_patients"`
* **Findings:**
  - Zero discrepancies found between `backend/config.py`, `configs/diagnostic_threshold.json`, `configs/clinical_protocol_version.json`, and `docs/phase_6_clinical_protocol.md`.
* **Status:** **PASS**

---

### Domain 5: Operating Threshold & Decision Consistency
* **Audit Standard:** Operating threshold must be locked at $\tau = 0.48$ on calibrated probabilities. Execution sequence must strictly follow:
  $$\text{CNN Logits} \to \text{Isotonic Calibration} \to \text{Calibrated Probability} \to \text{Threshold } (\tau = 0.48) \to \text{State}$$
* **Findings:**
  - Verified in `backend/model/inference_pipeline.py`, `configs/diagnostic_threshold.json`, `reports/phase_5_acceptance_test.md`, and unit tests (`tests/test_threshold.py`).
* **Status:** **PASS**

---

### Domain 6: Calibration Artifact Consistency
* **Audit Standard:** Calibration must employ monotonic empirical Isotonic Regression (`configs/calibrator_isotonic.joblib`) fitted on the held-out calibration partition.
* **Findings:**
  - Verified in `backend/model/calibration.py`, `backend/model/inference_pipeline.py`, and `configs/clinical_protocol_version.json`.
* **Status:** **PASS**

---

### Domain 7: Unit of Analysis & Aggregation Consistency
* **Audit Standard:** Independent statistical unit must be the **Child / Patient ($N = 300$)**, with multi-image aggregation governed by the locked arithmetic mean calibrated probability. Individual photos must never be treated as independent patients.
* **Findings:**
  - Verified in `docs/phase_6_clinical_protocol.md`, `reports/phase_6_sample_size_justification.md`, and `docs/STARD_AI_checklist.md`.
* **Status:** **PASS**

---

### Domain 8: Ethics Review Status & Blinding Consistency
* **Audit Standard:** Regulatory and ethical review status must strictly state `"Prepared for ethics submission (PENDING ETHICS APPROVAL)"` with zero fabricated approval numbers. Blinding must be described as `"blinded index-test assessment with independent reference-standard assessment"`.
* **Findings:**
  - `docs/ghs_erc_submission_checklist.md`: 11 items READY, 3 items PENDING (institutional letters, PACTR, indemnity), 2 items NOT APPLICABLE (justified).
  - Zero claims of "approved", "clinically proven", or "regulatory cleared".
  - Blinding accurately specifies: AI operator blinded to reference Hb/label; laboratory technologist blinded to AI score; AI receives nail photos only.
* **Status:** **PASS**

---

## 2. Audit Matrix Summary

| Domain | Audit Scope | Result | Notes |
|:---|:---|:---|:---|
| **1. Reference Analyzer** | Sysmex XN-350 / XN-550 & HemoCue 301 Hierarchy | **PASS** | Exact models, site mapping, and SLS method harmonized. |
| **2. Target Population** | 6–59 months (0–5m exploratory segregated) | **PASS** | Pediatric bounds locked; adult claims excluded. |
| **3. Diagnostic Cutoffs** | WHO 2024 Pediatric (10.5 g/dL & 11.0 g/dL) | **PASS** | Exact mathematical boundaries verified. |
| **4. Model Versioning** | `efficientnet_b0_v001` & associated tags | **PASS** | Centralized in `clinical_protocol_version.json`. |
| **5. Diagnostic Threshold** | $\tau = 0.48$ on Calibrated Probabilities | **PASS** | Locked threshold frozen across code and protocol. |
| **6. Probability Calibration** | Isotonic Regression Artifact | **PASS** | Serialized calibrator verified in pipeline. |
| **7. Unit of Analysis** | Child-Level Cluster & Mean Aggregation | **PASS** | Patient cluster integrity locked in SAP. |
| **8. Ethics & Blinding** | PENDING ETHICS APPROVAL & Blinded Assessment | **PASS** | Transparent governance without non-factual claims. |

---

## 3. Final Conclusion & Status Determination

All 8 governance and version-control consistency checks have achieved unanimous **PASS** status. The prospective clinical validation protocol, sample size justification, SOPs, and ethics submission package are internally consistent, technically locked, and ready for institutional ethical review.

$$\mathbf{FINAL\_STATUS = READY\_FOR\_ETHICS\_SUBMISSION}$$
